Recent Finacing
Recent Raise
Cabaletta Bio develops autologous CAAR-T cell therapies, using Penn-licensed CAR T technology to selectively eliminate autoantibody-producing B cells, advancing DSG3-CAART for mucosal pemphigus vulgaris with Penn collaboration.
